"We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio. "These ...
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...